GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Class II and III) to improve exercise capacity.

Ambrisentan is an endothelin receptor antagonist that blocks the endothelin A receptor on vascular smooth muscle cells and cardiac myocytes, preventing vasoconstriction and smooth muscle cell proliferation.

The recommended dose of Volibris is 5mg once daily. Some additional efficacy has been observed with 10mg once daily in patients with class III symptoms, however an increase in peripheral oedema has also been observed.

Patients with associated connective tissue disease may require 10mg once daily.

Volibris is currently the only drug licensed for patients with class II pulmonary arterial hypertension.

View Volibris drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more